HIPEC Surgery and Hemodynamics

Launched by MIRAY GÖZDE ÖZDEMIR · Apr 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Hyperthermic Intraperitoneal Chemotherapy (HIPEC), which is given after a type of surgery known as cytoreductive surgery (CRS). HIPEC involves warming up chemotherapy drugs and delivering them directly into the abdominal area during the surgery. While this method can be effective, it can also lead to some complications, like changes in blood pressure, problems with blood clotting, and issues with breathing and nutrition. The goal of this study is to better understand how HIPEC affects the body so that doctors can manage these challenges more effectively.

To participate in this trial, you must be at least 18 years old and scheduled for CRS with HIPEC. The study is open to patients classified as ASA II-III-IV, which refers to different levels of health before surgery. Unfortunately, those under 18 years old or those needing emergency surgery cannot join. If you participate, you can expect to be monitored closely to help researchers learn more about how this treatment works and how it can be improved for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years old Patients planned to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
• • ASA II-III-IV physical class
• Exclusion Criteria:
• • \<18 years
• • Emergency cases